

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1652

FEI HUANG, ET AL.

EXAMINER: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: 08/26/2003

FOR: METHODS OF USING EphA2 FOR PREDICTING ACTIVITY OF
COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN
TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE
PATHWAYS IN BREAST CELLS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Stephen C. D'Amico
Agent for Applicant
Reg. No. 46,652
Phone: 609-252-5289
Date: 5-9-07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1652

FEI HUANG, ET AL.

EXAMINER: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: 08/26/2003

FOR: METHODS OF USING EphA2 FOR PREDICTING ACTIVITY OF
COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN
TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE
PATHWAYS IN BREAST CELLS

Filed Via EFS-WEB
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a Search Report in a corresponding PCT International application. Copies of these references are enclosed herewith. Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p).


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Statement Under 37 C.F.R. § 1.704(d)

I, the undersigned agent, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application no more than 30 days prior to the filing of this Statement.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Stephen C. D'Amico
Agent for Applicant
Reg. No. 46,652
Phone: 609-252-5289
Date: 5-9-07